Discovery of piperlongumine as a potential novel lead for the development of senolytic agents

Aging

Volumn 8, Issue 11, 2016, Pages 2915-2926

  Wang, Yingying ^a,b   Chang, Jianhui ^a,b   Liu, Xingui ^a   Zhang, Xuan ^a   Zhang, Suping ^a,b   Zhang, Xin ^a,b   Zhou, Daohong ^a,b   Zheng, Guangrong ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

ABT 263; Aging; Piperlongumine; Reactive oxygen species; Senescent cells; Senolytic agents; Synergistic effect

Indexed keywords

1,3 DIOXOLANE DERIVATIVE; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; NAVITOCLAX; PIPERLONGUMININE; REACTIVE OXYGEN METABOLITE; SULFONAMIDE;

APOPTOSIS; CELL AGING; DRUG EFFECTS; FIBROBLAST; HUMAN; METABOLISM; ONCOGENE RAS; PHYSIOLOGY;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL AGING; DIOXOLANES; FIBROBLASTS; GENES, RAS; HUMANS; REACTIVE OXYGEN SPECIES; SULFONAMIDES;

EID: 85002142056     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.101100     Document Type: Article

References (73)

1. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B, Stein H, Dörken B, Jenuwein T, Schmitt CA. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature. 2005; 436:660-65. doi: 10.1038/nature03841.
2. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C, Pandolfi PP. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 2005; 436:725-30. doi: 10.1038/nature03918.
3. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007; 8:729-40. doi: 10.1038/nrm2233.
4. Prieur A, Peeper DS. Cellular senescence in vivo: a barrier to tumorigenesis. Curr Opin Cell Biol. 2008; 20:150-55. doi: 10.1016/j.ceb.2008.01.007.
5. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. Genes Dev. 2010; 24:2463-79. doi: 10.1101/gad.1971610.
6. Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol. 2013; 75:685-705. doi: 10.1146/annurev-physiol-030212-183653.
7. Aravinthan A. Cellular senescence: a hitchhiker's guide. Hum Cell. 2015; 28:51-64. doi: 10.1007/s13577-015-0110-x.
8. Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol. 2011; 192:547-56. doi: 10.1083/jcb.201009094.
9. Ohtani N, Takahashi A, Mann DJ, Hara E. Cellular senescence: a double-edged sword in the fight against cancer. Exp Dermatol. 2012 (Suppl 1); 21:1-4. doi: 10.1111/j.1600-0625.2012.01493.x.
10. Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest. 2013; 123:966-72. doi: 10.1172/JCI64098.
11. Salama R, Sadaie M, Hoare M, Narita M. Cellular senescence and its effector programs. Genes Dev. 2014; 28:99-114. doi: 10.1101/gad.235184.113.
12. Baker DJ, Wijshake T, Tchkonia T, LeBrasseur NK, Childs BG, van de Sluis B, Kirkland JL, van Deursen JM. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature. 2011; 479:232-36. doi: 10.1038/nature10600.
13. Baker DJ, Childs BG, Durik M, Wijers ME, Sieben CJ, Zhong J, Saltness RA, Jeganathan KB, Verzosa GC, Pezeshki A, Khazaie K, Miller JD, van Deursen JM. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature. 2016; 530:184-89. doi: 10.1038/nature16932.
14. Xu M, Tchkonia T, Ding H, Ogrodnik M, Lubbers ER, Pirtskhalava T, White TA, Johnson KO, Stout MB, Mezera V, Giorgadze N, Jensen MD, LeBrasseur NK, Kirkland JL. JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age. Proc Natl Acad Sci USA. 2015; 112:E6301-10. doi: 10.1073/pnas.1515386112.
15. Hall BM, Balan V, Gleiberman AS, Strom E, Krasnov P, Virtuoso LP, Rydkina E, Vujcic S, Balan K, Gitlin I, Leonova K, Polinsky A, Chernova OB, Gudkov AV. Aging of mice is associated with p16(Ink4a)-and β-galactosidase-positive macrophage accumulation that can be induced in young mice by senescent cells. Aging (Albany NY). 2016; 8:1294-315. doi: 10.18632/aging.100991.
16. Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature. 2013; 493:338-45. doi: 10.1038/nature11861.
17. Anisimov VN. Metformin for aging and cancer prevention. Aging (Albany NY). 2010; 2:760-74. doi: 10.18632/aging.100230.
18. Komarova EA, Antoch MP, Novototskaya LR, Chernova OB, Paszkiewicz G, Leontieva OV, Blagosklonny MV, Gudkov AV. Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/-mice. Aging (Albany NY). 2012; 4:709-14. doi: 10.18632/aging.100498.
19. Menendez JA, Joven J. One-carbon metabolism: an aging-cancer crossroad for the gerosuppressant metformin. Aging (Albany NY). 2012; 4:894-98. doi: 10.18632/aging.100523.
20. Ross C, Salmon A, Strong R, Fernandez E, Javors M, Richardson A, Tardif S. Metabolic consequences of long-term rapamycin exposure on common marmoset monkeys (Callithrix jacchus). Aging (Albany NY). 2015; 7:964-73. doi: 10.18632/aging.100843.
21. van Deursen JM. The role of senescent cells in ageing. Nature. 2014; 509:439-46. doi: 10.1038/nature13193.
22. Sharpless NE, Sherr CJ. Forging a signature of in vivo senescence. Nat Rev Cancer. 2015; 15:397-408. doi: 10.1038/nrc3960.
23. Zhu Y, Tchkonia T, Pirtskhalava T, Gower AC, Ding H, Giorgadze N, Palmer AK, Ikeno Y, Hubbard GB, Lenburg M, O'Hara SP, LaRusso NF, Miller JD, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015; 14:644-58. doi: 10.1111/acel.12344.
24. Kirkland JL, Tchkonia T. Clinical strategies and animal models for developing senolytic agents. Exp Gerontol. 2015; 68:19-25. doi: 10.1016/j.exger.2014.10.012.
25. Chang J, Wang Y, Shao L, Laberge RM, Demaria M, Campisi J, Janakiraman K, Sharpless NE, Ding S, Feng W, Luo Y, Wang X, Aykin-Burns N, et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med. 2016; 22:78-83. doi: 10.1038/nm.4010.
26. Zhu Y, Tchkonia T, Fuhrmann-Stroissnigg H, Dai HM, Ling YY, Stout MB, Pirtskhalava T, Giorgadze N, Johnson KO, Giles CB, Wren JD, Niedernhofer LJ, Robbins PD, Kirkland JL. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell. 2016; 15:428-35. doi: 10.1111/acel.12445.
27. Yosef R, Pilpel N, Tokarsky-Amiel R, Biran A, Ovadya Y, Cohen S, Vadai E, Dassa L, Shahar E, Condiotti R, Ben-Porath I, Krizhanovsky V. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat Commun. 2016; 7:11190. doi: 10.1038/ncomms11190.
28. Geiger H. Depleting senescent cells to combat aging. Nat Med. 2016; 22:23-24. doi: 10.1038/nm.4024.
29. Bezerra DP, Pessoa C, de Moraes MO, Saker-Neto N, Silveira ER, Costa-Lotufo LV. Overview of the therapeutic potential of piplartine (piperlongumine). Eur J Pharm Sci. 2013; 48:453-63. doi: 10.1016/j.ejps.2012.12.003.
30. Adams DJ, Dai M, Pellegrino G, Wagner BK, Stern AM, Shamji AF, Schreiber SL. Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs. Proc Natl Acad Sci USA. 2012; 109:15115-20. doi: 10.1073/pnas.1212802109.
31. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, Tolliday NJ, Golub TR, Carr SA, Shamji AF, Stern AM, Mandinova A, Schreiber SL, Lee SW. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature. 2011; 475:231-34. doi: 10.1038/nature10167.
32. Han SS, Son DJ, Yun H, Kamberos NL, Janz S. Piperlongumine inhibits proliferation and survival of Burkitt lymphoma in vitro. Leuk Res. 2013; 37:146-54. doi: 10.1016/j.leukres.2012.11.009.
33. Roh JL, Kim EH, Park JY, Kim JW, Kwon M, Lee BH. Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer. Oncotarget. 2014; 5:9227-38. doi: 10.18632/oncotarget.2402.
34. Gong LH, Chen XX, Wang H, Jiang QW, Pan SS, Qiu JG, Mei XL, Xue YQ, Qin WM, Zheng FY, Shi Z, Yan XJ. Piperlongumine induces apoptosis and synergizes with cisplatin or paclitaxel in human ovarian cancer cells. Oxid Med Cell Longev. 2014; 2014:906804. doi: 10.1155/2014/906804.
35. Liu JM, Pan F, Li L, Liu QR, Chen Y, Xiong XX, Cheng K, Yu SB, Shi Z, Yu AC, Chen XQ. Piperlongumine selectively kills glioblastoma multiforme cells via reactive oxygen species accumulation dependent JNK and p38 activation. Biochem Biophys Res Commun. 2013; 437:87-93. doi: 10.1016/j.bbrc.2013.06.042.
36. Randhawa H, Kibble K, Zeng H, Moyer MP, Reindl KM. Activation of ERK signaling and induction of colon cancer cell death by piperlongumine. Toxicol In Vitro. 2013; 27:1626-33. doi: 10.1016/j.tiv.2013.04.006.
37. Ginzburg S, Golovine KV, Makhov PB, Uzzo RG, Kutikov A, Kolenko VM. Piperlongumine inhibits NF-κB activity and attenuates aggressive growth characteristics of prostate cancer cells. Prostate. 2014; 74:177-86. doi: 10.1002/pros.22739.
38. Jin HO, Lee YH, Park JA, Lee HN, Kim JH, Kim JY, Kim B, Hong SE, Kim HA, Kim EK, Noh WC, Kim JI, Chang YH, et al. Piperlongumine induces cell death through ROS-mediated CHOP activation and potentiates TRAIL-induced cell death in breast cancer cells. J Cancer Res Clin Oncol. 2014; 140:2039-46. doi: 10.1007/s00432-014-1777-1.
39. Wang Y, Wu X, Zhou Y, Jiang H, Pan S, Sun B. Piperlongumine Suppresses Growth and Sensitizes Pancreatic Tumors to Gemcitabine in a Xenograft Mouse Model by Modulating the NF-kappa B Pathway. Cancer Prev Res (Phila). 2016; 9:234-44. doi: 10.1158/1940-6207.CAPR-15-0306.
40. Zheng J, Son DJ, Gu SM, Woo JR, Ham YW, Lee HP, Kim WJ, Jung JK, Hong JT. Piperlongumine inhibits lung tumor growth via inhibition of nuclear factor kappa B signaling pathway. Sci Rep. 2016; 6:26357. doi: 10.1038/srep26357.
41. Chen SY, Liu GH, Chao WY, Shi CS, Lin CY, Lim YP, Lu CH, Lai PY, Chen HR, Lee YR. Piperlongumine Suppresses Proliferation of Human Oral Squamous Cell Carcinoma through Cell Cycle Arrest, Apoptosis and Senescence. Int J Mol Sci. 2016; 17:E616. doi: 10.3390/ijms17040616.
42. Caserta TM, Smith AN, Gultice AD, Reedy MA, Brown TL. Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis. 2003; 8:345-52. doi: 10.1023/A:1024116916932.
43. Walsh CM. Grand challenges in cell death and survival: apoptosis vs. necroptosis. Front Cell Dev Biol. 2014; 2:3. doi: 10.3389/fcell.2014.00003.
44. Wang Y, Wang JW, Xiao X, Shan Y, Xue B, Jiang G, He Q, Chen J, Xu HG, Zhao RX, Werle KD, Cui R, Liang J, et al. Piperlongumine induces autophagy by targeting p38 signaling. Cell Death Dis. 2013; 4:e824. doi: 10.1038/cddis.2013.358.
45. Liu QR, Liu JM, Chen Y, Xie XQ, Xiong XX, Qiu XY, Pan F, Liu D, Yu SB, Chen XQ. Piperlongumine inhibits migration of glioblastoma cells via activation of ROSdependent p38 and JNK signaling pathways. Oxid Med Cell Longev. 2014; 2014:653732. doi: 10.1155/2014/653732.
46. Li J, Sharkey CC, King MR. Piperlongumine and immune cytokine TRAIL synergize to promote tumor death. Sci Rep. 2015; 5:9987. doi: 10.1038/srep09987.
47. Duan C, Zhang B, Deng C, Cao Y, Zhou F, Wu L, Chen M, Shen S, Xu G, Zhang S, Duan G, Yan H, Zou X. Piperlongumine induces gastric cancer cell apoptosis and G2/M cell cycle arrest both in vitro and in vivo. Tumour Biol. 2016; 37:10793-804. doi: 10.1007/s13277-016-4792-9.
48. Cerecetto H, López GV. Antioxidants derived from vitamin E: an overview. Mini Rev Med Chem. 2007; 7:315-38. doi: 10.2174/138955707780059871.
49. Boskovic ZV, Hussain MM, Adams DJ, Dai M, Schreiber SL. Synthesis of piperlogs and analysis of their effects on cells. Tetrahedron. 2013; 69:7559-67. doi: 10.1016/j.tet.2013.05.080.
50. Cottini F, Hideshima T, Suzuki R, Tai YT, Bianchini G, Richardson PG, Anderson KC, Tonon G. Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. Cancer Discov. 2015; 5:972-87. doi: 10.1158/2159-8290.CD-14-0943.
51. Patel K, Chowdhury N, Doddapaneni R, Boakye CH, Godugu C, Singh M. Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer. J Pharm Sci. 2015; 104:4417-26. doi: 10.1002/jps.24637.
52. Hao JQ, Li Q, Xu SP, Shen YX, Sun GY. Effect of lumiracoxib on proliferation and apoptosis of human nonsmall cell lung cancer cells in vitro. Chin Med J (Engl). 2008; 121:602-07.
53. Kaefer A, Yang J, Noertersheuser P, Mensing S, Humerickhouse R, Awni W, Xiong H. Mechanismbased pharmacokinetic/pharmacodynamic metaanalysis of navitoclax (ABT-263) induced thrombocytopenia. Cancer Chemother Pharmacol. 2014; 74:593-602. doi: 10.1007/s00280-014-2530-9.
54. Han JG, Gupta SC, Prasad S, Aggarwal BB. Piperlongumine chemosensitizes tumor cells through interaction with cysteine 179 of IκBa kinase, leading to suppression of NF-κB-regulated gene products. Mol Cancer Ther. 2014; 13:2422-35. doi: 10.1158/1535-7163.MCT-14-0171.
55. Bharadwaj U, Eckols TK, Kolosov M, Kasembeli MM, Adam A, Torres D, Zhang X, Dobrolecki LE, Wei W, Lewis MT, Dave B, Chang JC, Landis MD, et al. Drugrepositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer. Oncogene. 2015; 34:1341-53. doi: 10.1038/onc.2014.72.
56. Chen Y, Liu JM, Xiong XX, Qiu XY, Pan F, Liu D, Lan SJ, Jin S, Yu SB, Chen XQ. Piperlongumine selectively kills hepatocellular carcinoma cells and preferentially inhibits their invasion via ROS-ER-MAPKs-CHOP. Oncotarget. 2015; 6:6406-21. doi: 10.18632/oncotarget.3444.
57. Golovine K, Makhov P, Naito S, Raiyani H, Tomaszewski J, Mehrazin R, Tulin A, Kutikov A, Uzzo RG, Kolenko VM. Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma. Cancer Biol Ther. 2015; 16:743-49. doi: 10.1080/15384047.2015.1026511.
58. Golovine KV, Makhov PB, Teper E, Kutikov A, Canter D, Uzzo RG, Kolenko VM. Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells. Prostate. 2013; 73:23-30. doi: 10.1002/pros.22535.
59. Han SS, Tompkins VS, Son DJ, Kamberos NL, Stunz LL, Halwani A, Bishop GA, Janz S. Piperlongumine inhibits LMP1/MYC-dependent mouse B-lymphoma cells. Biochem Biophys Res Commun. 2013; 436:660-65. doi: 10.1016/j.bbrc.2013.06.012.
60. Jarvius M, Fryknäs M, D'Arcy P, Sun C, Rickardson L, Gullbo J, Haglund C, Nygren P, Linder S, Larsson R. Piperlongumine induces inhibition of the ubiquitinproteasome system in cancer cells. Biochem Biophys Res Commun. 2013; 431:117-23. doi: 10.1016/j.bbrc.2013.01.017.
61. Kong EH, Kim YJ, Kim YJ, Cho HJ, Yu SN, Kim KY, Chang JH, Ahn SC. Piplartine induces caspase-mediated apoptosis in PC-3 human prostate cancer cells. Oncol Rep. 2008; 20:785-92.
62. Lee HN, Jin HO, Park JA, Kim JH, Kim JY, Kim B, Kim W, Hong SE, Lee YH, Chang YH, Hong SI, Hong YJ, Park IC, et al. Heme oxygenase-1 determines the differential response of breast cancer and normal cells to piperlongumine. Mol Cells. 2015; 38:327-35. doi: 10.14348/molcells.2015.2235.
63. Li W, Wen C, Bai H, Wang X, Zhang X, Huang L, Yang X, Iwamoto A, Liu H. JNK signaling pathway is involved in piperlongumine-mediated apoptosis in human colorectal cancer HCT116 cells. Oncol Lett. 2015; 10:709-15.
64. Makhov P, Golovine K, Teper E, Kutikov A, Mehrazin R, Corcoran A, Tulin A, Uzzo RG, Kolenko VM. Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death. Br J Cancer. 2014; 110:899-907. doi: 10.1038/bjc.2013.810.
65. Niu M, Shen Y, Xu X, Yao Y, Fu C, Yan Z, Wu Q, Cao J, Sang W, Zeng L, Li Z, Liu X, Xu K. Piperlongumine selectively suppresses ABC-DLBCL through inhibition of NF-κB p65 subunit nuclear import. Biochem Biophys Res Commun. 2015; 462:326-31. doi: 10.1016/j.bbrc.2015.04.136.
66. Ryu J, Kim MJ, Kim TO, Huh TL, Lee SE. Piperlongumine as a potential activator of AMPactivated protein kinase in HepG2 cells. Nat Prod Res. 2014; 28:2040-43. doi: 10.1080/14786419.2014.919283.
67. Shrivastava S, Jeengar MK, Thummuri D, Naidu VG. Piperlongumine inhibits growth potential of gastric cancer cells by targeting PI3K/Akt/mTOR signaling pathway. Eur J Cancer. 2014; 50:S9-9. doi: 10.1016/S0959-8049(14)70032-2.
68. Shrivastava S, Kulkarni P, Thummuri D, Jeengar MK, Naidu VG, Alvala M, Redddy GB, Ramakrishna S. Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspasedependent apoptosis in human triple-negative breast cancer cells. Apoptosis. 2014; 19:1148-64. doi: 10.1007/s10495-014-0991-2.
69. Wang F, Mao Y, You Q, Hua D, Cai D. Piperlongumine induces apoptosis and autophagy in human lung cancer cells through inhibition of PI3K/Akt/mTOR pathway. Int J Immunopathol Pharmacol. 2015; 28:362-73. doi: 10.1177/0394632015598849.
70. Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, Chu Q, Giaccone G, Khaira D, Ramalingam SS, Ranson MR, Dive C, McKeegan EM, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012; 18:3163-69. doi: 10.1158/1078-0432.CCR-11-3090.
71. Schoenwaelder SM, Jarman KE, Gardiner EE, Hua M, Qiao J, White MJ, Josefsson EC, Alwis I, Ono A, Willcox A, Andrews RK, Mason KD, Salem HH, et al. Bcl-xLinhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood. 2011; 118:1663-74. doi: 10.1182/blood-2011-04-347849.
72. Vogler M, Hamali HA, Sun XM, Bampton ET, Dinsdale D, Snowden RT, Dyer MJ, Goodall AH, Cohen GM. BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. Blood. 2011; 117:7145-54. doi: 10.1182/blood-2011-03-344812.
73. Lujambio A. To clear, or not to clear (senescent cells)? That is the question. BioEssays. 2016 (Suppl 1); 38:S56-64. doi: 10.1002/bies.201670910.